Free Trial
NASDAQ:BWAY

BrainsWay (BWAY) Stock Price, News & Analysis

BrainsWay logo
$10.00
+0.05 (+0.50%)
(As of 10/31/2024 ET)

About BrainsWay Stock (NASDAQ:BWAY)

Key Stats

Today's Range
$9.89
$10.16
50-Day Range
$7.15
$10.28
52-Week Range
$3.37
$10.61
Volume
45,470 shs
Average Volume
94,984 shs
Market Capitalization
$166.78 million
P/E Ratio
200.04
Dividend Yield
N/A
Price Target
$13.17
Consensus Rating
Moderate Buy

Company Overview

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

BrainsWay Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
59th Percentile Overall Score

BWAY MarketRank™: 

BrainsWay scored higher than 59% of companies evaluated by MarketBeat, and ranked 512th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BrainsWay has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    BrainsWay has only been the subject of 2 research reports in the past 90 days.

  • Read more about BrainsWay's stock forecast and price target.
  • Earnings Growth

    Earnings for BrainsWay are expected to grow by 100.00% in the coming year, from $0.06 to $0.12 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BrainsWay is 200.04, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 133.70.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BrainsWay is 200.04, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 131.93.

  • Price to Book Value per Share Ratio

    BrainsWay has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about BrainsWay's valuation and earnings.
  • Percentage of Shares Shorted

    0.28% of the outstanding shares of BrainsWay have been sold short.
  • Short Interest Ratio / Days to Cover

    BrainsWay has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BrainsWay has recently increased by 59.31%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BrainsWay does not currently pay a dividend.

  • Dividend Growth

    BrainsWay does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.28% of the outstanding shares of BrainsWay have been sold short.
  • Short Interest Ratio / Days to Cover

    BrainsWay has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BrainsWay has recently increased by 59.31%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    BrainsWay has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for BrainsWay this week, compared to 2 articles on an average week.
  • Search Interest

    Only 8 people have searched for BWAY on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added BrainsWay to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BrainsWay insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.00% of the stock of BrainsWay is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 30.11% of the stock of BrainsWay is held by institutions.

  • Read more about BrainsWay's insider trading history.
Receive BWAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BrainsWay and its competitors with MarketBeat's FREE daily newsletter.

BWAY Stock News Headlines

FY2025 EPS Estimate for BrainsWay Decreased by Analyst
$5k to $1.3m in just 3 trades
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
HC Wainwright Has Bearish Estimate for BrainsWay Q3 Earnings
BrainsWay's (BWAY) "Buy" Rating Reiterated at HC Wainwright
BrainsWay Expands Deep TMS Reach in East Asia
See More Headlines

BWAY Stock Analysis - Frequently Asked Questions

BrainsWay's stock was trading at $6.48 at the beginning of 2024. Since then, BWAY stock has increased by 54.3% and is now trading at $10.00.
View the best growth stocks for 2024 here
.

BrainsWay Ltd. (NASDAQ:BWAY) released its earnings results on Tuesday, August, 6th. The company reported $0.04 EPS for the quarter. The company earned $10.01 million during the quarter, compared to the consensus estimate of $9.40 million. BrainsWay had a trailing twelve-month return on equity of 1.45% and a net margin of 1.67%.

BrainsWay (BWAY) raised $30 million in an IPO on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor acted as the underwriter for the IPO.

Top institutional shareholders of BrainsWay include Good Life Advisors LLC (0.33%).

Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that BrainsWay investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Novo Nordisk A/S (NVO) and AppLovin (APP).

Company Calendar

Last Earnings
8/06/2024
Today
10/31/2024
Next Earnings (Confirmed)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:BWAY
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.17
High Stock Price Target
$16.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+32.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-4,200,000.00
Pretax Margin
2.14%

Debt

Sales & Book Value

Annual Sales
$36.43 million
Book Value
$2.50 per share

Miscellaneous

Free Float
13,509,000
Market Cap
$165.95 million
Optionable
Not Optionable
Beta
1.26
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:BWAY) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners